Endocrine Abstracts

Acromegaly is a rare clinical disorder characterized by progressive somatic disfigurement and a wide range of systemic complications which include gonadotrophic dysfunction, menstrual abnormalities and infertility. Thus, pregnancy in patients with acromegaly is a rare and challenging medical situation. Furthermore, the evidence about the use of somatostatin analogs (SSAs) during pregnancy in patients with acromegaly and its outcomes is still limited. Here we describe the clinical characteristics and outcomes of two patients with acromegaly who were treated with SSA during pregnancy, which add to the previous reports of similar cases. Case 1: 19 y.o. female, G1P0 with a GH- and prolactin-producing pituitary tumour (macroadenoma) previously treated with transesphenoidal surgery for tumor resection and cabergolide 0.5 mg 4x/w, octreotide LAR 30 mg IM every 28d. She continues on octreotide LAR 30 mg IM every 28d since week 9 of pregnancy achieving normal term pregnancy (38w3d gestation, 3200 g, 51 cm newborn) and 76, 34 and 30% reduction in GH and IGF1 levels and tumour size reduction, respectively. Case 2: 25 y.o. female, G1P0 with a GH- and prolactin-producing pituitary tumour (macroadenoma) previously treated with transesphenoidal surgery for tumor resection and bromocriptine 2.5 mg QD PO. She is started on lanreotide ATG 60 mg Q3 every 28 days since week 11 of pregnancy achieving normal term pregnancy (39w2d, 3120 g, 49 cm newborn) and a 66, 64 and 14.2% reduction in GH and IGF1 levels and tumour size reduction, respectively. These cases suggest that SSAs during pregnancy in patients with acromegaly reduce GH and IGF1 levels and tumor size with no effect on fetal growth or development.

Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.

Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector